TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bypass vs. Ecmo in Lung Transplantation (BELT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. The study population will be all patients requiring cardiopulmonary support while undergoing lung transplantation at our institution.~Exclusion Criteria:~1. Patients undergoing concomitant cardiac operations with indication for obligate use of cardiopulmonary bypass~2. Patient with specific anatomy that require full cardiac decompression such as severe pulmonary hypertension or large heart that are shifted severely into the left chest~3. Patients with high likelihood of significant pleural bleeding that will require returning the blood back into the cardiotomy reservoir~4. Patients bridged to transplant with ECMO~5. Cystic fibrosis/bronchiectasis/resistant infection patients where surgeon will need to remove both lungs prior to implantation~6. Patients who the surgeon feels would be better served with CPB rather than ECMO- These patients will be entered into a registry and followed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cardiopulmonary Bypass (Type: None): There will be 40 patients placed on cardiopulmonary bypass during lung transplantation.
- Extracorporeal Membrane Oxygenation (Type: None): There will be 40 patients placed on ECMO during lung transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Absorbable Sutures in Perineal Laceration Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Able to sign informed consent~* Vaginal laceration that requires sutures but does not involve the anal sphincter (third-degree tear) or rectal mucosa (fourth-degree tear)~Exclusion Criteria:~* Inability to speak and understand English or Spanish~* Previous diagnosis of vulvodynia, dyspareunia, or other chronic vulvar pain syndrome~* Extensive perineal warts or vulvar varicosities

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Mobility and Cognition in Older Adults Using Non-Invasive Brain Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Having executive dysfunction (defined as score below 11 out of a possible 13 in the Montreal Cognitive Assessment -MoCA- executive score index)~* Age 60 years and older~* English speaking~* Able to ambulate 10m independently without any gait aid (eg. walker, cane)~Exclusion Criteria:~* Unable to understand or communicate in English~* Parkinsonism or any neurological disorder with residual motor deficit (eg. Major stroke, epilepsy)~* Musculoskeletal disorder detected by clinical examination which affects gait performance -Active osteoarthritis affecting lower limbs (American College of Rheumatology criteria)~* Severe depression operationalized as Geriatric Depression Scale (GDS) score\>10~TMS specific exclusion criteria:~* Persons with metal anywhere in the head, excluding the mouth, including shrapnel, and screws and clips from surgical procedures~* Persons with cardiac pacemakers, implanted medication pumps, electrodes inside the heart~* Unstable heart disease~* Persons with increased intracranial pressure, as in acute large infarctions or trauma~* Previous major stroke, history seizure, Parkinson D, Huntington D.~* History of schizophrenia/schizo-affective disorder, substance use disorder within 1 year of study

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- rTMS Active (Type: EXPERIMENTAL): High frequency pulsed repetitive magnetic stimulation at 100 % resting motor threshold will be delivered using a figure of 8 air film cooled coil attached to the Magstim® Rapid 2 machine. Resting motor threshold will be determined minimum energy needed to elicit the a reliable visible contraction in the contra-lateral first interosseous muscle using single pulse rTMS applied to the area between C1-C3 using the 10-20 international EEG electrode system. For stimulation, the coil will be positioned on the scalp corresponding to F4 then F3 electrode position using the 10-20 international EEG system. Real stimulation will consist of delivering 1200 pulses at 20 hz frequency to F4 location followed by the same stimulation to F3. The total time needed to deliver pulses is 20 minutes.
- rTMS Sham (Type: PLACEBO_COMPARATOR): Sham stimulation will also involve delivering the same stimulus but with angulation of the coil at 45 degrees, which will give similar scalp sensation but unlikely to deliver magnetic stimulation to the cortex

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must be diagnosed as hematopoiesis disorders and receiving hematopoietic stem cells transplantation.~2. Steroid dependent or refractory classic chronic GVHD disease defined as modified National Institutes of Health criteria(2014) below at any time post-hematopoietic cell transplant(post-HCT)~   1. Dependent disease, defined as, when glucocorticoid (prednisolone doses greater than or equal to(\<=) 0.25mg/kg/day or \<=0.5mg/kg every other day(prednisolone doses) due to recurrence or progression of cGVHD manifestations, it is considered as steroid-dependent disease if the lowest tapering dose of the second occasion is equal or higher than the lowest tapering dose of the first occasion~  2. Refractory disease, defined as, when cGVHD manifestations progress despite the use of a regime containing glucocorticoid (prednisolone at \>=1mg/kg/day for at least 1 week) or persist without improvement despite continued treatment with glucocorticoid (prednisolone at \>=0.5mg/kg/day or 1mg/kg every other day) for at least 4 weeks.~3. Participants must be receiving baseline systemic glucocorticoid therpy for cGVHD at study entry. The dose of steroids must be stable for 14 days prior to starting anlotinib.~4. At the time of trial enrollment, participants may be receiving other immunosuppressive therapies in addition to glucocorticoids. Immunosuppressant doses must be stable for 14 days prior to starting anlotinib.~5. Neutrophil≥1.5×109/L，platelet≥50×109/L~6. Karnofsky or Lansky performance status\>=60~7. Participants should sign the agreement.~Exclusion Criteria:~1. Known or suspected active acute GVHD.~2. Current treatment with a tyrosine kinase inhibitor, purin analogs or other cancer chemotherapy in the 4weeks prior to starting study drug.~3. Concomitant use of warfarin or other Vitamin K antogonists.~4. Known bleeding disorders or hemophilia.~5. Known history of human immunodeficiency virus or active with hepatitis C. virus or hepatitis B virus.~6. Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicine or recent infection requiring systemic treatment .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- therapy (Type: EXPERIMENTAL): therapy with 1 arm. Anlotinib 8mg qd po。

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 7-18 days of age at Visit 1~* Singleton birth~* Gestational age of 37-42 weeks~* Birth weight of 2500 g (5 lbs 8 oz) or more~* Parent or legal guardian agrees not to enroll infant in another interventional clinical study while participating in this study~* Signed informed consent and use of PHI for infant and birth mother~* Receipt of three protocol-compliant Baseline stool samples~Infants receiving formula:~* Exclusively receiving infant formula for at least 24 hours prior to randomization~* Parent(s) or legal guardian has full intention to exclusively feed study formula during the study period~Infants receiving human milk:~* Mother has intention to exclusively provide mother's-own breast milk for the duration of the study~Exclusion Criteria:~* Caesarean delivery~* Infant consumption of donor milk prior to randomization/registration~* Maternal antibiotic use within 48 hours prior to or at time of delivery~* Maternal antibiotic use while providing mother's-own breast milk to infant~* Infant use of systemic antibiotics prior to randomization/registration~* Any signs of an acute infection (i.e. fever, diarrhea) at randomization/registration~* Weight at Visit 1 is \<95% of birth weight~* Infant use of probiotics~* Evidence of significant feeding difficulties~* Infant was born large for gestational age~* History of underlying metabolic or chronic disease or congenital malformation~* Infant is immunocompromised~Infants receiving human milk:~* Consumption of infant formula from 1 day of age

- Gender: ALL
- Minimum Age: 7 Days
- Maximum Age: 18 Days
- Healthy Volunteers: t

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): None
- Investigational (Type: EXPERIMENTAL): None
- Mother's-own Breast Milk (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed non-small cell lung cancer (NSCLC)~  * Must have clinical and/or pathological evidence of pleural spread~ * Primary tumor must be resectable as assessed by the attending thoracic surgeon~* Patients who have received or are currently receiving two-to-four courses of standard front-line chemotherapy are eligible~PATIENT CHARACTERISTICS:~* Must be medically fit to tolerate surgery~* No CTCAE v3.0 grade III-IV elevations in liver transaminases~* Bilirubin ≤ 1.5 mg/dL~* No known HIV infection~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior treatment for NSCLC except pleurodesis or standard front-line chemotherapy~* No prior pemetrexed disodium chemotherapy~* No prior mantle radiotherapy~* No concurrent chemotherapy or radiotherapy during the active study treatment period~  * Post-operative radiotherapy will be administered as clinically indicated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Photodynamic Therapy (Type: EXPERIMENTAL): PDT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: histologic or cytologic evidence of stage IIIB (with malignant pleural effusion) or stage IV NSCLC; no prior chemotherapy; measurable disease; disease that is amenable to biopsy; age 18 years; Zubrod performance status 0-2; adequate bone marrow, hepatic and renal function; signed informed consent.~Exclusion Criteria: prior chemotherapy or radiation therapy to target lesions; pregnant or lactating women; symptomatic or uncontrolled CNS metastases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven lymphoma (Hodgkin's or non-Hodgkin's)~* Age \> 18 y/o and \< 70 y/o~* WHO score \< or = 2~* Life expectancy \> 6 mo~* Left ventricular ejection fraction \> 50%~* Informed consent~Exclusion Criteria:~* Previous chemotherapy using anthracyclines~* History of radiation therapy~* History of congestive heart failure~* History of chronic renal insufficiency~* Contra indication to MR examination~* Atrial fibrillation and significant arrhythmia~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients \>18 years of age~2. Able to provide informed consent, or presence of a legally authorized representative able and willing to provide informed consent~3. Candidates for total abdominal colectomy due to severe, complicated FCDC per consulting surgeon and team providing care~4. Subjects must meet criteria for operative management of FCDC (find in detailed protocol)~Exclusion Criteria:~1. Children (\<18 years of age)~2. Allergy or hypersensitivity reaction to study medications: Vancomycin, Metronidazole, GoLytely~3. Intra-operative evidence of colonic perforation~4. Intra-operative evidence of colonic necrosis~5. Pregnancy (this will be ruled out by a urine test at the time of indication for surgery)~6. Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- total abdominal colectomy (Type: ACTIVE_COMPARATOR): the standard of care for fulminant clostridium difficile colitis is a total abdominal colectomy
- Ileal diversion and lavage (Type: EXPERIMENTAL): The tested intervention in this trial will be: intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution, that will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Biopsy proven EBV(+) or KSHV(+) malignancy~* Relapsed/refractory disease failing \> 2 prior therapies~* Measurable, non-bony disease (at least one lesion on radiographic or physical exam assessment measuring \> 2 cm in longest axis)~* KS patients with skin-only disease must have cutaneous lesions amenable to four 3 mm punch biopsies during the course of the study~* Eastern Cooperative Oncology Group (ECOG) performance status \< 2~* Life expectancy of greater than 12 weeks~* Patients must be able to lie flat for at least 60 minutes and fit on a PET-CT scanner~* Ability to comply with an oral drug regimen~* Females of childbearing potential must have a negative pregnancy test at screening~* Patients must have normal organ and marrow function as defined below within 14 days of study entry~Exclusion Criteria:~* Patients with HIV-associated primary central nervous system lymphoma~* Radiotherapy or chemotherapy ending within 14 days of study enrollment~* Patients currently on other protease inhibitors~* Chronic diarrhea~* Acute, active infection within 14 days of enrollment~* Patients on active treatment for hypo- or hyperthyroidism~* End-stage liver disease unrelated to tumor~* Hepatitis B or hepatitis C infection~* Use of any other type of investigational agent or treatment concurrently or within 28 days before the first dose of study treatment~* History of iodine hypersensitivity~* Females who are pregnant or breastfeeding~* Physical or psychiatric conditions that in the estimation of the investigator place the patient at high risk of toxicity, non-compliance, or inability to complete the study requirements~* Use of drugs to treat or prevent herpesvirus infections~* Essential medication that is known to interact with nelfinavir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nelfinavir (Type: EXPERIMENTAL): Nelfinavir twice daily on days 1-14 of a 14-day cycle for 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Moving 2 Mindful (M2M) Study: Mindfulness Group + Ecological Momentary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* two parents in the home~* an adolescent who is between 14 and 18 years of age~* marital distress and/or problematic interparental conflict (based on parent or youth reports)~* youth reports of stress or anxiety~Exclusion Criteria:~* two parents in the home, but they are pursuing legal divorce or separation~* parents are not willing to receive marital education/support~* adolescents are severely clinically depressed or report suicidal ideation at baseline

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Learning to BREATHE Plus (Type: EXPERIMENTAL): It is a 6-week manualized program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University. Adolescents will be sent ecological momentary intervention text messages several times a day (with reminders, encouragement, and guides to practice mindfulness), and also have access to an on demand online library of mindfulness resources.
- Health and wellness (Type: ACTIVE_COMPARATOR): It is a 6-week program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of a Novel Concept for a Manual Toothbrush Broscyl®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children attending school aged between 8 and 15 years~* OR adults aged from 18 to 45 years~* OR elderly persons aged more than 65 years old~* Presenting at least one incisive, one canine, one premolar and one molar in each quadrant~* Able to brush their own teeth at least twice a day~* Persons who have provided written informed consent~* Persons covered by the national health insurance agency~Exclusion Criteria:~* Persons with acute periodontal disease~* Persons in a period of postsurgical healing~* Persons with an acute oral pain syndrome~* Persons undergoing orthodontic treatment with a fixed brace~* Persons not covered by the national health insurance agency~* Pregnant women~* The use of adjuvants

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Children (Type: OTHER): None
- Adults (Type: OTHER): None
- Elderly people (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Implementation of an Evidence Based Smoking Cessation Strategy (SMOCC) for Patients With COPD in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* COPD~* Smoking~* Age 40 years or over~Exclusion Criteria:~* Under control of lung specialist~* Not Dutch-speaking~* Serious physical of psychiatric comorbidity~* Under 40 years of age

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues